PD-1 Combined With Pyrotinib for Chemotherapy Failure HER2 Insertion Mutation Advanced NSCLC
Recruiting · NCT04144569 · Interventional (participants receive a specific treatment) · Lead sponsor: Yongchang Zhang
View the official record on ClinicalTrials.gov →Interventions studied
PD-1 Combined With Pyrotinib
What this trial is about
The purpose of this study is to assess the safety and effectiveness of PD-1 Combined With Pyrotinib for First-line chemotherapy failed HER2 Insertion Mutation Positive Advanced Non-small Cell Lung Cancer
Who can take part
Age range
18 Years to 75 Years
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Phase 2
Study type
Interventional (participants receive a specific treatment)
Inclusion criteria
- Advanced non-small cell lung cancer confirmed by histology or cytology
- HER2 insertion mutation-positive
- Failure with first-line standard chemotherapy
- with measurable lesions.
Exclusion criteria
- no measurable tumor lesions
- Patients received PD-1 or Pyrotinib before
Where it is running
1 location listed.
- Hunan Provincal Tumor Hospital - Changsha, Hunan, China